Johnson & Johnson (JNJ)

Healthcare • Drug Manufacturers - General

Beobachten

$230,75

Price

+1,54%

Change

555,94 Mrd. $

Market Cap

18,75

P/E Ratio

Neumann-Score Stock Analysis

out of 100

Beobachten

Valuation??/100

Profitability??/100

Growth??/100

Unlock Score Details

Become a member and get access to all analyses.

Become a Member

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care product ...

CEO

Joaquin Duato

Employees

138.100

Country